by Jon Rappoport, No More Fake News:
The US drug maker Pfizer and German partner BioNTech SE said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide US distribution by the end of the year, shaving several years off the typical vaccine development timeline. The US study is part of a broader, global program already underway in Germany, where BioNTech is based. Dosing there began last month.
Pfizer has begun dosing Americans with its experimental coronavirus vaccines for its clinical trial in collaboration with BioNTech SE, the pharmaceutical giant announced Tuesday.